22 - References

References
352
The Maudsley® Prescribing Guidelines in Psychiatry
CHAPTER 3
References
Marcantoni WS, et al. A systematic review and meta-­analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 – January 2019. J Affect Disord 2020; 277:831–841.
Papakostas GI, et al. Efficacy of esketamine augmentation in major depressive disorder: a meta-­analysis. J Clin Psychiatry 2020; 81:19r12889.
Meshkat S, et al. Oral ketamine for depression: an updated systematic review. World J Biol Psychiatry 2023; 24:545–557.
Wilkinson ST, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant
data meta-­analysis. Am J Psychiatry 2018; 175:150–158.
Witt K, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-­analysis of treatment trials.
Aust N Z J Psychiatry 2020; 54:29–45.
Alnefeesi Y, et al. Real-­world effectiveness of ketamine in treatment-­resistant depression: a systematic review and meta-­analysis. J Psychiatr
Res 2022; 151:693–709.
Terao I, et al. Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole
and lithium as augmentative treatments for treatment-­resistant unipolar depression: a systematic review and network meta-­analysis. J Affect
Disord 2024; 346:49–56.
Capuzzi E, et al. Long-­term efficacy of intranasal esketamine in treatment-­resistant major depression: a systematic review. Int J Mol Sci 2021;
22:9338.
Beck K, et al. Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: a systematic review and meta-­analysis. JAMA Netw Open 2020; 3:e204693.
aan het Rot M, et al. Safety and efficacy of repeated-­dose intravenous ketamine for treatment-­resistant depression. Biol Psychiatry 2010;
67:139–145.
Short B, et al. Side-­effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry 2018; 5:65–78.
Goh KK, et al. Lamotrigine augmentation in treatment-­resistant unipolar depression: a comprehensive meta-­analysis of efficacy and safety. J
Psychopharmacol 2019; 33:700–713.
Papadimitropoulou K, et al. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with
treatment-­resistant depression: a systematic review and network meta-­analysis. Curr Med Res Opin 2017; 33:701–711.
Guo Q, et al. Efficacy and safety of eight enhanced therapies for treatment-­resistant depression: a systematic review and network meta-­
analysis of RCTs. Psychiatry Res 2024; 339:116018.
Joffe RT, et  al. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990;
32:241–251.
Anderson IM. Drug treatment of depression: reflections on the evidence. Adv Psychiatr Treat 2003; 9:11–20.
Nierenberg AA, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D
report. Am J Psychiatry 2006; 163:1519–1530.
Iosifescu DV, et al. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-­resistant major
depressive disorder. J Clin Psychiatry 2005; 66:1038–1042.
Abraham G, et al. T3 augmentation of SSRI resistant depression. J Affect Disord 2006; 91:211–215.
Kelly TF, et al. Long term augmentation with T3 in refractory major depression. J Affect Disord 2009; 115:230–233.
Parmentier T, et al. The use of triiodothyronine (T3) in the treatment of bipolar depression: a review of the literature. J Affect Disord 2018;
229:410–414.
Nuñez NA, et al. Augmentation strategies for treatment resistant major depression: a systematic review and network meta-­analysis. J Affect
Disord 2022; 302:385–400.
Garlow SJ, et al. The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major
depressive disorder. J Psychiatr Res 2012; 46:1406–1413.